ACRV Stock Summary and Trading Ideas (Acrivon Therapeutics | NASDAQ:ACRV)

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Company matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Acrivon Therapeutics trades on the NASDAQ stock market under the symbol ACRV.

As of March 20, 2023, ACRV stock price declined to $11.61 with 202,129 million shares trading.

ACRV has a market cap of $242.47 million. This is considered a Small Cap stock.

The top ETF exchange traded funds that ACRV belongs to (by Net Assets): IWM, IWN, IWO, IWC.

ACRV support price is $17.76 and resistance is $22.24 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACRV stock will trade within this expected range on the day.